Urothelial Carcinoma of the Renal Pelvis and Ureter Clinical Trials
2 recruiting trials for Urothelial Carcinoma of the Renal Pelvis and Ureter. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Urothelial Carcinoma of the Renal Pelvis and Ureter clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Nagoya University (1), Nucleix Ltd. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy (drug, 1 trial), followed by Bladder EpiCheck.
Track Urothelial Carcinoma of the Renal Pelvis and Ureter trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy. Chemotherapy is generally used...
Bladder EpiCheck European Haematuria Study
The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Urothelial Carcinoma of the Renal Pelvis and Ureter, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Urothelial Carcinoma of the Renal Pelvis and Ureter, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Urothelial Carcinoma of the Renal Pelvis and Ureter, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.